C4 Therapeutics (CCCC) Non-Current Deffered Revenue: 2019-2025
Historic Non-Current Deffered Revenue for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $19.9 million.
- C4 Therapeutics' Non-Current Deffered Revenue fell 30.58% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 30.58%. This contributed to the annual value of $28.5 million for FY2024, which is 30.45% up from last year.
- Per C4 Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $19.9 million for Q3 2025, which was down 5.97% from $21.1 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Non-Current Deffered Revenue registered a high of $50.9 million during Q1 2021, and its lowest value of $15.8 million during Q1 2023.
- In the last 3 years, C4 Therapeutics' Non-Current Deffered Revenue had a median value of $21.1 million in 2025 and averaged $22.1 million.
- As far as peak fluctuations go, C4 Therapeutics' Non-Current Deffered Revenue tumbled by 62.62% in 2022, and later spiked by 45.99% in 2024.
- Over the past 5 years, C4 Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $24.4 million in 2021, then slumped by 30.67% to $16.9 million in 2022, then increased by 29.12% to $21.8 million in 2023, then spiked by 30.45% to $28.5 million in 2024, then tumbled by 30.58% to $19.9 million in 2025.
- Its Non-Current Deffered Revenue stands at $19.9 million for Q3 2025, versus $21.1 million for Q2 2025 and $25.1 million for Q1 2025.